Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE MAT2A INHIBITOR (SYH2039)OBTAINS CLINICAL TRIAL APPROVAL

VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE MAT2A INHIBITOR (SYH2039)OBTAINS CLINICAL TRIAL APPROVAL

March 19, 2024

a240318_00.png

a240318_01.png

Previous: VOLUNTARY ANNOUNCEMENT - ANTIBODY-DRUG CONJUGATE SYS6023 OBTAINS CLINICAL TRIAL APPROVAL

Next: CSPC Innovation Included in FTSE Global Equity Index Series

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |

Wechat